Compare SATL & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | HUMA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.3M | 236.0M |
| IPO Year | N/A | N/A |
| Metric | SATL | HUMA |
|---|---|---|
| Price | $1.87 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 3.8M | ★ 4.9M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,684,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $698.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.91 |
| 52 Week High | $5.12 | $5.48 |
| Indicator | SATL | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 29.70 |
| Support Level | $1.95 | $1.04 |
| Resistance Level | $2.25 | $1.17 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.33 | 10.58 |
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.